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Most people with hypertension or diabetes will develop structural heart disease, which might 
cause renal water and salt retention and, eventually, symptoms and signs of congestion: in 
one word, heart failure (1). Most modern definitions of heart failure couple the notions of 
symptoms, (eg:- breathless or ankle swelling), an abnormality on imaging (such as a reduced 
left ventricular ejection fraction (LVEF)) and raised plasma concentrations of natriuretic 
peptides (2). For many individuals, there must be a long, pre-clinical phase of cardiac 
dysfunction (3,4). Intervening before the onset of symptoms may offer the best opportunity to 
delay their onset, change the disease-trajectory and prolong active life. This requires 
screening of asymptomatic people, usually those at greater risk of developing heart failure, to 
identify pre-clinical cardiac dysfunction. This is an enormous undertaking. The population to 
be screened should be well-defined, the screening tools should be simple and robust and the 
definitions of what is abnormal must be clear. For those who test ‘positive’, the risk of 
morbidity, disability and death should be sufficiently high to warrant intervention and there 
should be an actionable intervention that reduces these risks.  
 
There is some evidence that asymptomatic individuals with a substantially reduced LVEF 
(ie:<40%) might benefit from treatment with ACE-inhibitors, beta-blockers, 
mineralocorticoid receptor antagonists and probably statins, especially those with a history of 
myocardial infarction (5). However, screening of asymptomatic patients with hypertension or 
diabetes identifies rather few people with an LVEF <40% (6), even though many may have 
had an undiagnosed myocardial infarction (7).  Measurement of global longitudinal strain 
(GLS) might be more sensitive than LVEF in identifying more subtle LV systolic 
dysfunction, but it requires more sophisticated technology and equipment, personnel and 
skills, and additional time for obtaining good quality images and for their analysis (8). Of 
note, there is no evidence that treating a patient with an impaired GLS is beneficial when 
LVEF is normal. There are many other sophisticated methods of imaging cardiac function 
that are associated with a greater risk of events but none has been shown to be useful in 
selecting patients for treatment (9). On the other hand, there is some evidence that selecting 
patients for treatment based on plasma concentrations of natriuretic peptides may be useful 
(10-12).   
 
In the current issue of this journal, Morbach and colleagues used the Characteristics and 
Course of Heart Failure Stages A-B and Determinants of Progression (STAAB) cohort study 
to assess the prevalence of heart failure precursor stages in the general population (13). They 
enrolled a representative sample (n=~5,000) of residents of Wuerzburg (n=124,297), 
Germany, aged 30 to 79 years. In the derivation cohort (n=2,473), 42% of participants were 
in Stage A (that is risk factors for heart failure but without evidence of cardiac dysfunction on 
imaging) and 17% were in Stage B (evidence of structural heart disease, including a reduced 
LVEF, diastolic dysfunction or valve disease) but without symptoms such as exertional 
breathlessness or ankle swelling. Surprisingly, only seven patients had structural heart disease 
with symptoms (ie:- undiagnosed heart failure; Stage C). Interestingly, they also identified a 
substantial proportion of participants (n=131, 5%) with structural heart disease who had no 
risk factors (called Stage B-not-A). These findings were confirmed in an internal validation 
cohort (n=2,492), in which 9% were found to be in Stage B-not-A.   
 
A large proportion of Stage B-not-A individuals were young women (78%; mean age 47 
years) who were reported to have impaired systolic function (32%) or a dilated left ventricle 
(72%) by echocardiography, but they often had a normal plasma NT-proBNP  (median: 54 
(28-94) ng/L, which is the expected median value for healthy women aged 40-50 years (14)) 
and most (95%) had normal left atrial volumes. Their plasma NT-proBNP and left atrial 
volumes were similar to those in Stage A (NT-proBNP 56 (27-106) ng/L, and 7% left atrial 
dilation, respectively), and also similar to those without risk factors (NT-proBNP 42 (21-78) 
ng/L) and 2% left atrial dilation).  
 
Compared to patients in Stage B-not-A, those in Stage B were about 15 years older and were 
more likely to have valve disease or left atrial dilatation (22%) and had a lower mean LVEF 
(56 (7)% vs 59 (6) %) and higher NT-proBNP (median 95 (54-179) ng/L). This suggests that 
participants in Stage B-not-A had less or milder structural heart disease compared to Stage B 
(Figure).  
 
 
 
Omissions and errors will have accounted for some people in Stage B having no record of 
risk factors. Definitions of structural heart disease are arbitrary. Values for some people with 
disease will remain in the ‘normal’ range and some people without disease will be beyond the 
95% confidence limits of the normal range; these will often be people who go to the gym or 
engage in sports (15), which was not uncommon for these individuals. The high prevalence of 
LV dilation as a criterion for structural heart disease for those identified as "B-not-A" might 
also be because measurements were overestimated when adjusted for body size: by 
definition, those B-not-A could not be obese. Finally, measurement precision and 
reproducibility may account for some patients being classified inaccurately.  
      
The left atrium is a thin-walled cardiac chamber that is exposed to the same internal pressure 
as the much thicker-walled LV during diastole. A chronic increase in LV filling pressure, 
regardless of cause, should lead to atrial remodelling, increasing the risk of atrial fibrillation 
and reducing atrial performance (16) thereby contributing to the development of heart failure. 
A rise in atrial and ventricular diastolic pressures and wall stress should also cause plasma 
concentrations of NT-proBNP to increase. NT-proBNP is one of the most powerful 
prognostic markers in patients with cardiovascular disease but is fairly agnostic as to the 
cause of cardiac dysfunction. Up to 50% of patients with hypertension, coronary artery 
disease or diabetes have elevated plasma concentrations of NT-proBNP, which indicates an 
adverse CV outcome (17). Therefore, a dilated and dysfunctional left atrium and elevated 
plasma NT-proBNP might be the most appropriate markers to quantify cardiac dysfunction 
rather than measurements of LV structure and function that are complex and prone to 
measurement error. NT-proBNP might be the preferred screening test for population studies 
and in primary care because it can be measured at the same time of other routine blood tests, 
with little additional costs. Low plasma concentrations do not require further investigation of 
cardiac function and provide reassurance to patients and their doctors. Emerging evidence 
suggests that identification and treatment of individuals at risk of heart failure who have 
modest increases in plasma NT-proBNP improves adverse cardiac remodelling, and perhaps 
outcome (10-12). The reasons for any increase in NT-proBNP should be considered. Atrial 
fibrillation may be identified by physical examination and confirmed by electrocardiography. 
Renal dysfunction can be identified by measuring serum creatinine in the same blood test as 
NT-proBNP. Patients with a history of hypertension who do not have a murmur or history of 
myocardial infarction and who have only modest increases in plasma NT-proBNP (perhaps 
<500ng/L) are likely to have left ventricular hypertrophy and developing diastolic LV 
dysfunction.  Those with more marked increases in plasma NT-proBNP or with a murmur or 
history of myocardial infarction should have an echocardiogram. 
 
In summary, if cardiac imaging suggests that there is structural heart disease but this is not 
associated with a dilated left atrium and elevated plasma concentrations of NT-proBNP, then 
either the imaging measurements are wrong or the structural disease is having no significant 
effect on cardiac performance. It is likely that Stage B-not-A includes many people with an 
excellent prognosis. Long-term follow-up is required to prove that this is the case.   
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